(NASDAQ: HUMA) Humacyte's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Humacyte's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast HUMA's revenue for 2024 to be $198,870,870, with the lowest HUMA revenue forecast at $107,175,918, and the highest HUMA revenue forecast at $290,565,821. On average, 2 Wall Street analysts forecast HUMA's revenue for 2025 to be $2,329,885,366, with the lowest HUMA revenue forecast at $1,492,126,943, and the highest HUMA revenue forecast at $3,167,643,790.
In 2026, HUMA is forecast to generate $9,435,053,288 in revenue, with the lowest revenue forecast at $8,752,699,946 and the highest revenue forecast at $10,117,406,631.